Results of the multicenter, randomized, open-label CLOSURE I trial—first released at a session of late-breaking clinical trials at the 2010 AHA Scientific Sessions—have now been published in New England Journal of Medicine. Compared with medical therapy alone, percutaneous closure of a patent foramen ovale did not significantly reduce the incidence of stroke or transient ischemic attack (adjusted HR 0.78, 95% CI 0.45–1.35, P = 0.37 = 0.37) in the 909 patients who had previously experienced such an event.
ORIGINAL RESEARCH PAPER
Furlan, A. J. et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N. Engl. J. Med. 366, 991–999 (2012)
Rights and permissions
About this article
Cite this article
Closure of patent foramen ovale does not prevent stroke. Nat Rev Cardiol 9, 312 (2012). https://doi.org/10.1038/nrcardio.2012.47
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.47
